Emergent BioSolutions (EBS) Receives Positive Data From FDA for its BioThrax - Achieves $30 Million Milestone Payment
Tweet Send to a Friend
Emergent BioSolutions Inc. (NYSE: EBS) announced that BioThrax (Anthrax Vaccine Adsorbed), has been granted a shelf life extension from 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
